Last reviewed 2026-04-23 · How we verify

AERAS-402

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Study of AERAS-402 in Healthy Infants (PHASE1, PHASE2)
• Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults (PHASE2)
• A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB (PHASE2)
• A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB (PHASE1)
• A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402 (PHASE1)
• Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A (PHASE1)
• A Study to Evaluate Safety and Immunogenicity of AERAS-402 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.